secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-044783
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma FY2024 net loss $43.3M; cash $69.8M funds operations into 2027
------------------------------------------------------------------------------

- Net loss of $43.3M in FY2024 vs $29.5M in FY2023; R&D expenses rose $3.5M to $20.9M driven by alvelestat and setrusumab.
- Cash and equivalents of $69.8M as of Dec 31, 2024; expected to fund operations into 2027.
- Phase 3 Orbit study of setrusumab in OI progressing; second interim analysis expected mid-2025, final Q4 2025.
- Alvelestat granted EU Orphan Designation for AATD-LD in Q1 2025; partnering discussions ongoing.
- Pre-commercial activities for setrusumab in Europe advancing with NICE and GBA scientific advice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025044783/0000950170-25-044783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025044783/mreo-20250326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer